Clinical Role of β-Lactam/β-Lactamase Inhibitor Combinations

[1]  E. Bergogne-Bérézin.  Current Guidelines for the Treatment and Prevention of Nosocomial Infections , 1999, Drugs.

[2]  Peter A. Todd,et al.  Amoxicillin/Clavulanic Acid , 1990, Drugs.

[3]  C. Nord,et al.  Effect of beta-lactamase inhibitors on beta-lactamases from anaerobic bacteria , 1992, European Journal of Clinical Microbiology and Infectious Diseases.

[4]  M. Thamer,et al.  Does dose matter? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  P. Pizzo.  Chapter 58 – Fever and Neutropenia , 2004 .

[6]  I. Jado,et al.  Antimicrobial susceptibility and pneumococcal serotypes. , 2002, The Journal of antimicrobial chemotherapy.

[7]  J Prieto,et al.  Antimicrobial resistance: a class effect? , 2002, The Journal of antimicrobial chemotherapy.

[8]  A. Georgopoulos,et al.  Antibacterial activity of oral antibiotics against community-acquired respiratory pathogens from three European countries. , 2002, The Journal of antimicrobial chemotherapy.

[9]  M. Sanz,et al.  Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. , 2002, The Journal of antimicrobial chemotherapy.

[10]  R. Auckenthaler.  Pharmacokinetics and pharmacodynamics of oral beta-lactam antibiotics as a two-dimensional approach to their efficacy. , 2002, The Journal of antimicrobial chemotherapy.

[11]  T. Calandra,et al.  Guidelines for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer , 2002 .

[12]  R. Davidson,et al.  Prevention and management of infections in patients without a spleen. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  W. Craig.  Does the dose matter? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  P. Davey,et al.  Association between antibiotic resistance and community prescribing: a critical review of bias and confounding in published studies. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  C E Nord,et al.  Effect of antimicrobial agents on the ecological balance of human microflora. , 2001, The Lancet. Infectious diseases.

[16]  R. Nichols,et al.  Clinical presentations of soft-tissue infections and surgical site infections. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  B. Thinkhamrop,et al.  Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  D. Livermore,et al.  Detection of β-lactamase-mediated resistance , 2001 .

[19]  P. Moreau,et al.  Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  S. Marba,et al.  Reduction in colonization and nosocomial infection by multiresistant bacteria in a neonatal unit after institution of educational measures and restriction in the use of cephalosporins. , 2001, American journal of infection control.

[21]  G. Doern,et al.  Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  W. Bilker,et al.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  J. Rosenblatt,et al.  Multicenter Survey of the Changing In Vitro Antimicrobial Susceptibilities of Clinical Isolates of Bacteroides fragilis Group, Prevotella, Fusobacterium, Porphyromonas, and PeptostreptococcusSpecies , 2001, Antimicrobial Agents and Chemotherapy.

[24]  G. Eliopoulos,et al.  New beta-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  V. Cheng,et al.  Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  G. Barlow,et al.  Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  T. Karasawa,et al.  Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections. , 2001, Oral microbiology and immunology.

[28]  M. Pfaller,et al.  Global view of antimicrobial resistance. Findings of the SENTRY Antimicrobial Surveillance Program, 1997-1999. , 2001, Postgraduate medicine.

[29]  M. Nicolas-Chanoine,et al.  Epidemiological Survey of Amoxicillin-Clavulanate Resistance and Corresponding Molecular Mechanisms in Escherichia coliIsolates in France: New Genetic Features ofblaTEM Genes , 2000, Antimicrobial Agents and Chemotherapy.

[30]  S. Essack.  Treatment options for extended-spectrum β-lactamase-producers , 2000 .

[31]  P. Lister.  β‐Lactamase Inhibitor Combinations with Extended‐Spectrum Penicillins: Factors Influencing Antibacterial Activity against Enterobacteriaceae and Pseudomonas aeruginosa , 2000 .

[32]  D. Paterson.  Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). , 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  D. Talan,et al.  Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  Michael J Fine,et al.  Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  L. Mandell,et al.  Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  R. Bonnet,et al.  Prevalence of β-Lactamases among 1,072 Clinical Strains of Proteus mirabilis: a 2-Year Survey in a French Hospital , 2000, Antimicrobial Agents and Chemotherapy.

[37]  Anthony D. Harris,et al.  Risk Factors for Recovery of Ampicillin-Sulbactam-Resistant Escherichia coli in Hospitalized Patients , 2000, Antimicrobial Agents and Chemotherapy.

[38]  J. Steckelberg,et al.  Clinical aspects of antimicrobial resistance. , 2000, Mayo Clinic proceedings.

[39]  V. Banssillon.  Bactériologic analysis of infected dog and cate bites. Emergency medicine animal bite infection study group , 1999 .

[40]  M. Fine,et al.  Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. , 1999, Archives of internal medicine.

[41]  Rie Nagano,et al.  Carbapenem Derivatives as Potential Inhibitors of Various β-Lactamases, Including Class B Metallo-β-Lactamases , 1999, Antimicrobial Agents and Chemotherapy.

[42]  B. Randhawa,et al.  Bactericidal action of ampicillin/sulbactam against intracellular mycobacteria. , 1999, International journal of antimicrobial agents.

[43]  A. Bayer,et al.  Treatment of Experimental Staphylococcal Endocarditis Due to a Strain with Reduced Susceptibility In Vitro to Vancomycin: Efficacy of Ampicillin-Sulbactam , 1999, Antimicrobial Agents and Chemotherapy.

[44]  F. Goldstein.  Penicillin-resistant Streptococcus pneumoniae: selection by both β-lactam and non-β-lactam antibiotics , 1999 .

[45]  R. Finberg,et al.  Fever and neutropenia--how to use a new treatment strategy. , 1999, The New England journal of medicine.

[46]  Sean C. Sweetman,et al.  Martindale: The Complete Drug Reference , 1999 .

[47]  G. Paul,et al.  Inhibitor-resistant TEM beta-lactamases: phenotypic, genetic and biochemical characteristics. , 1999, The Journal of antimicrobial chemotherapy.

[48]  I. Gould.  A review of the role of antibiotic policies in the control of antibiotic resistance. , 1999, The Journal of antimicrobial chemotherapy.

[49]  C. Sanders,et al.  Clavulanate Induces Expression of the Pseudomonas aeruginosa AmpC Cephalosporinase at Physiologically Relevant Concentrations and Antagonizes the Antibacterial Activity of Ticarcillin , 1999, Antimicrobial Agents and Chemotherapy.

[50]  A. J. Wright.  Symposium on Antimicrobial Agents—Part VIThe Penicillins , 1999 .

[51]  A. Goldstone,et al.  The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. , 1999, The Journal of antimicrobial chemotherapy.

[52]  H. Derendorf,et al.  Pharmacokinetic properties of beta-lactamase inhibitors. , 1999, International journal of clinical pharmacology and therapeutics.

[53]  E. Goldstein,et al.  Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. , 1999, The New England journal of medicine.

[54]  J. Picazo,et al.  In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents. , 1999, The Journal of antimicrobial chemotherapy.

[55]  J. Karlowsky,et al.  Characterization of the inoculum effect with Haemophilus influenzae and beta-lactams. , 1999, Diagnostic microbiology and infectious disease.

[56]  Corrado,et al.  Prospective study of the risk of Clostridium difficile diarrhoea in elderly patients following treatment with cefotaxime or piperacillin–tazobactam , 1998, Alimentary pharmacology & therapeutics.

[57]  J. Ariza,et al.  Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. , 1998, The Journal of antimicrobial chemotherapy.

[58]  R. Chioléro,et al.  Prospective Randomized Comparison of Imipenem-Cilastatin and Piperacillin-Tazobactam in Nosocomial Pneumonia or Peritonitis , 1998, Antimicrobial Agents and Chemotherapy.

[59]  S. Amyes.  Genes and spectrum: the theoretical limits. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[60]  G. Drusano.  Infection in the intensive care unit: beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  S. J. Knott,et al.  In Vitro Activities of Oral β-Lactams at Concentrations Achieved in Humans against Penicillin-Susceptible and -Resistant Pneumococci and Potential to Select Resistance , 1998, Antimicrobial Agents and Chemotherapy.

[62]  A. Leelarasamee.  Burkholderia pseudomallei: the unbeatable foe? , 1998, The Southeast Asian journal of tropical medicine and public health.

[63]  Claude Martin,et al.  Comparison of Concentrations of Sulbactam-Ampicillin Administered by Bolus Injections or Bolus plus Continuous Infusion in Tissues of Patients Undergoing Colorectal Surgery , 1998, Antimicrobial Agents and Chemotherapy.

[64]  M. Territo,et al.  Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[65]  C. Brun-Buisson,et al.  Treatment of ventilator-associated pneumonia with piperacillin-tazobactam/amikacin versus ceftazidime/amikacin: a multicenter, randomized controlled trial. VAP Study Group. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  J. Ariza,et al.  Epidemiology and Successful Control of a Large Outbreak Due to Klebsiella pneumoniae Producing ExtendedSpectrum β-Lactamases , 1998, Antimicrobial Agents and Chemotherapy.

[67]  J. Weiner,et al.  Mechanism of suppression of piperacillin resistance in enterobacteria by tazobactam , 1997, Antimicrobial agents and chemotherapy.

[68]  A. Bisno,et al.  Diagnosis and Management of Group A Streptococcal Pharyngitis: A Practice Guideline , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[69]  Ronald N. Jones,et al.  Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). , 1997, Diagnostic microbiology and infectious disease.

[70]  F. Tenover,et al.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. , 1997, The Journal of antimicrobial chemotherapy.

[71]  R. Quenzer,et al.  Pharmacoeconomic analysis of selected antibiotics in lower respiratory tract infection. , 1997, The American journal of managed care.

[72]  J. Williams,et al.  beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[73]  W. Craig.  The future--can we learn from the past? , 1997, Diagnostic microbiology and infectious disease.

[74]  G. Gibbons,et al.  Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[75]  D. Landman,et al.  Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[76]  L. Rice,et al.  Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[77]  E. Bouza,et al.  Broad-spectrum -lactam antibiotics with -lactamase inhibitors , 1996 .

[78]  I. Lauder,et al.  Hospital antibiotic prescribing successfully modified by 'immediate concurrent feedback'. , 1996, British journal of clinical pharmacology.

[79]  Á. Asensio,et al.  Colonization and Infection With Methicillin-Resistant Staphylococcus aureus: Associated Factors and Eradication , 1996, Infection Control & Hospital Epidemiology.

[80]  D. Sirot.  Extended-spectrum plasmid-mediated beta-lactamases. , 1995, The Journal of antimicrobial chemotherapy.

[81]  F. Higashitani,et al.  Effects of tazobactam on the frequency of the emergence of resistant strains from Enterobacter cloacae, Citrobacter freundii, and Proteus vulgaris (beta-lactamase derepressed mutants). , 1995, The Journal of antibiotics.

[82]  M. Paesmans,et al.  Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer , 1995, Antimicrobial agents and chemotherapy.

[83]  J. Jorgensen,et al.  Comparison of Ampicillin‐Sulbactam and Ticarcillin‐Clavulanic Acid in Patients With Chronic Renal Failure: Effects of Differential Pharmacokinetics on Serum Bactericidal Activity , 1994, Pharmacotherapy.

[84]  P. Davey,et al.  Assessing cost effectiveness of antimicrobial treatment: monotherapy compared with combination therapy. , 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[85]  G. Eliopoulos,et al.  Activity of ampicillin-sulbactam and oxacillin in experimental endocarditis caused by beta-lactamase-hyperproducing Staphylococcus aureus , 1993, Antimicrobial Agents and Chemotherapy.

[86]  B. Bäckstrand,et al.  Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections , 1992, Antimicrobial Agents and Chemotherapy.

[87]  D. Larrey,et al.  Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases. , 1992, Gut.

[88]  G. S. Gilbert,et al.  Worldwide clinical experience with sultamicillin. , 1989, APMIS. Supplementum.

[89]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[90]  A. van der Kuy,et al.  [The penicillins]. , 1974, Tijdschrift voor ziekenverpleging.